The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.
 
Robert H. Getzenberg
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
Consulting or Advisory Role - Veru
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru; Veru; Veru
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi; Veru
 
Mark Christopher Markowski
No Relationships to Disclose
 
Gary Barnette
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
 
Darryl Patrick
Consulting or Advisory Role - Veru
 
Mitchell S. Steiner
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
Patents, Royalties, Other Intellectual Property - Veru